The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
In first-line NSCLC the drug beats chemo, and not Keytruda.
And the company might one day follow Galapagos into decentralised manufacturing.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.